163 related articles for article (PubMed ID: 26005891)
21. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.
Saleh MI; Obeidat AR; Anter HA; Khanfar AA
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):1030-5. PubMed ID: 26173631
[TBL] [Abstract][Full Text] [Related]
22. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
Liesveld JL; Phillips GL; Becker M; Constine LS; Friedberg J; Andolina JR; Milner LA; DeBolt J; Smudzin T; Hyrien O; Erickson-Miller CL; Johnson BM; Dawson KL; Chen Y
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380
[TBL] [Abstract][Full Text] [Related]
23. Economic assessment of eltrombopag in the treatment of thrombocytopenia.
Romano F; Ruggeri M; Coretti S; Giannini EG; Sacchini D; Annichiarico BE; Marchetti M; Rodeghiero F; Lidonnici D
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):713-20. PubMed ID: 26176754
[TBL] [Abstract][Full Text] [Related]
24. Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient.
Duic JP; Grewal J; McConie K; Staszewski H; Haas J; Kesari S
J Neurooncol; 2012 Jan; 106(2):427-9. PubMed ID: 21833801
[No Abstract] [Full Text] [Related]
25. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
[TBL] [Abstract][Full Text] [Related]
26. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia.
Zhang L; Zhang M; Du X; Cheng Y; Cheng G
Br J Haematol; 2020 Apr; 189(2):369-378. PubMed ID: 31943136
[TBL] [Abstract][Full Text] [Related]
28. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
[TBL] [Abstract][Full Text] [Related]
29. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
Trautmann K; Jakob C; von Grünhagen U; Schleyer E; Brümmendorf TH; Siegert G; Ehninger G; Platzbecker U
Thromb Haemost; 2012 Aug; 108(2):397-8. PubMed ID: 22739569
[No Abstract] [Full Text] [Related]
30. Eltrombopag in patients with chronic liver disease.
Giannini EG; Afdhal NH
Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
[TBL] [Abstract][Full Text] [Related]
31. Eltrombopag use in a patient with Wiskott-Aldrich syndrome.
Gabelli M; Marzollo A; Notarangelo LD; Basso G; Putti MC
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643468
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.
Winer ES; Safran H; Karaszewska B; Bauer S; Khan D; Doerfel S; Burgess P; Kalambakas S; Mostafa Kamel Y; Forget F
Int J Hematol; 2017 Dec; 106(6):765-776. PubMed ID: 28864871
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales.
Allen R; Bryden P; Grotzinger KM; Stapelkamp C; Woods B
Value Health; 2016; 19(5):614-22. PubMed ID: 27565278
[TBL] [Abstract][Full Text] [Related]
34. Eltrombopag in thrombocytopenia.
Lawson A
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
[No Abstract] [Full Text] [Related]
35. Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.
Sarpatwari A; Franklin JM; Avorn J; Seeger JD; Landon JE; Kesselheim AS
Clin Pharmacol Ther; 2015 Feb; 97(2):186-93. PubMed ID: 25670524
[TBL] [Abstract][Full Text] [Related]
36. Chronic lymphocytic leukemia-associated refractory immune thrombocytopenia successfully treated with eltrombopag.
Chang H; Shih LY
Tumori; 2015 Apr; 101(2):e49-50. PubMed ID: 25702666
[TBL] [Abstract][Full Text] [Related]
37. Treatment of severe thrombocytopenia associated with systemic lupus erythematosus in pregnancy with eltrombopag: A case report and literature review.
Leng Q; Wang W; Wang Y; Wu L
J Clin Pharm Ther; 2021 Apr; 46(2):532-538. PubMed ID: 33277725
[TBL] [Abstract][Full Text] [Related]
38. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
[No Abstract] [Full Text] [Related]
39. Platelet activation and function during eltrombopag treatment in immune thrombocytopenia.
Haselboeck J; Pabinger I; Ay C; Koder S; Panzer S
Ann Hematol; 2012 Jan; 91(1):109-13. PubMed ID: 21553010
[TBL] [Abstract][Full Text] [Related]
40. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia.
Favier R; Feriel J; Favier M; Denoyelle F; Martignetti JA
Pediatrics; 2013 Sep; 132(3):e793-5. PubMed ID: 23940247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
